{
    "organizations": [],
    "uuid": "24e133d66cb65a69171b29725b9955d1c58730fb",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kite-sangamo-therapeutics-announce/brief-kite-sangamo-therapeutics-announce-collaboration-to-develop-next-generation-engineered-cell-therapies-for-treatment-of-cancer-idUSFWN1QC0JE",
    "ord_in_thread": 0,
    "title": "BRIEF-Kite, Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For Treatment Of Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - Sangamo Therapeutics Inc:\n* KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER\n* SANGAMO THERAPEUTICS - KITE TO RECEIVE EXCLUSIVE LICENSE TO LEVERAGE SANGAMOâ€˜S GENE EDITING TECHNOLOGY IN ALLOGENEIC AND AUTOLOGOUS CELL THERAPY PROGRAMS IN ONCOLOGY\n* SANGAMO THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, SANGAMO WILL RECEIVE AN UPFRONT PAYMENT OF $150 MILLION\n* SANGAMO THERAPEUTICS INC - UNDER TERMS, SANGAMO IS ELIGIBLE TO RECEIVE UP TO $3.01 BILLION IN POTENTIAL PAYMENTS\n* SANGAMO THERAPEUTICS INC - KITE WILL BE RESPONSIBLE FOR AGREED UPON EXPENSES INCURRED BY SANGAMO\n* SANGAMO THERAPEUTICS INC - CO WOULD ALSO RECEIVE TIERED ROYALTIES ON SALES OF POTENTIAL FUTURE PRODUCTS RESULTING FROM COLLABORATION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-22T20:16:00.000+02:00",
    "crawled": "2018-02-23T15:44:04.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "sangamo",
        "therapeutic",
        "inc",
        "kite",
        "gilead",
        "company",
        "sangamo",
        "therapeutic",
        "announce",
        "collaboration",
        "develop",
        "engineered",
        "cell",
        "therapy",
        "treatment",
        "cancer",
        "sangamo",
        "therapeutic",
        "kite",
        "receive",
        "exclusive",
        "license",
        "leverage",
        "sangamo",
        "gene",
        "editing",
        "technology",
        "allogeneic",
        "autologous",
        "cell",
        "therapy",
        "program",
        "oncology",
        "sangamo",
        "therapeutic",
        "inc",
        "term",
        "agreement",
        "sangamo",
        "receive",
        "upfront",
        "payment",
        "million",
        "sangamo",
        "therapeutic",
        "inc",
        "term",
        "sangamo",
        "eligible",
        "receive",
        "billion",
        "potential",
        "payment",
        "sangamo",
        "therapeutic",
        "inc",
        "kite",
        "responsible",
        "agreed",
        "upon",
        "expense",
        "incurred",
        "sangamo",
        "sangamo",
        "therapeutic",
        "inc",
        "co",
        "would",
        "also",
        "receive",
        "tiered",
        "royalty",
        "sale",
        "potential",
        "future",
        "product",
        "resulting",
        "collaboration",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}